Hyaluronate - parathyroid hormone peptide conjugate for transdermal treatment of osteoporosis
SCIE
SCOPUS
- Title
- Hyaluronate - parathyroid hormone peptide conjugate for transdermal treatment of osteoporosis
- Authors
- CHO, Minsoo; Han, Seulgi; Kim, Hyemin; Kim, Ki Su; HAHN, SEI KWANG
- Date Issued
- 2018-03
- Publisher
- TAYLOR & FRANCIS LTD
- Abstract
- Human parathyroid hormone 1-34 fragment (PTH1-34) has been used as a FDA-approved therapeutics to treat osteoporosis by daily subcutaneous injection. In this work, we successfully developed PTH1-34 conjugated hyaluronic acid (HA) for the transdermal treatment of osteoporosis with improved patient compliance. HA-PTH1-34 conjugate was synthesized by the coupling reaction between aldehyde group introduced to HA and amine group of PTH1-34. After characterization by gel permeation chromatography (GPC) and ELISA, the biological effect of HA-PTH1-34 conjugate on the proliferation of human osteoblast cells was confirmed by in vitro calcium colorimetric assay and cAMP assay. Two-photon microscopy clearly visualized the effective skin penetration of FITC modified HA-PTH1-34 conjugate. The transdermally delivered HA-PTH1-34 conjugates elevated the blood calcium concentration for more than 2days, reflecting the feasibility for the treatment of osteoporosis.
- URI
- https://oasis.postech.ac.kr/handle/2014.oak/94990
- DOI
- 10.1080/09205063.2017.1399001
- ISSN
- 0920-5063
- Article Type
- Article
- Citation
- JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, vol. 29, no. 7-9, page. 793 - 804, 2018-03
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.